Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necitumumab and Abemaciclib in Stage IV NSCLC
NCT02411591Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoints: Dose Limiting Toxicities and Progression Free Survival Rate at 3 months. Started Jun 2015; status: completed.
02
Drugs
abemaciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02411591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411591.